Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.

Frenck RW Jr, Ervin J, Chu L, Abbanat D, Spiessens B, Go O, Haazen W, van den Dobbelsteen G, Poolman J, Thoelen S, Ibarra de Palacios P.

Lancet Infect Dis. 2019 Jun;19(6):631-640. doi: 10.1016/S1473-3099(18)30803-X. Epub 2019 May 9.

PMID:
31079947
2.

Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.

Queenan AM, Dowling DJ, Cheng WK, Faé K, Fernandez J, Flynn PJ, Joshi S, Brightman SE, Ramirez J, Serroyen J, Wiertsema S, Fortanier A, van den Dobbelsteen G, Levy O, Poolman J.

Vaccine. 2019 Jan 3;37(1):80-89. doi: 10.1016/j.vaccine.2018.11.028. Epub 2018 Nov 23.

PMID:
30478007
3.

Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants.

Inoue M, Ogawa T, Tamura H, Hagiwara Y, Saito Y, Abbanat D, van den Dobbelsteen G, Hermans P, Thoelen S, Poolman J, Ibarra de Palacios P.

Hum Vaccin Immunother. 2018;14(9):2150-2157. doi: 10.1080/21645515.2018.1474316. Epub 2018 Jun 28.

4.

Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

van Westen E, Poelen MCM, van den Dobbelsteen GPJM, Oloo EO, Ochs MM, Rots NY, van Els CACM.

PLoS One. 2018 Mar 6;13(3):e0193650. doi: 10.1371/journal.pone.0193650. eCollection 2018.

5.

Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine.

Abbanat D, Davies TA, Amsler K, He W, Fae K, Janssen S, Poolman JT, van den Dobbelsteen GPJM.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00123-17. doi: 10.1128/CVI.00123-17. Print 2017 Dec.

6.

Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.

Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, Dreyer AM, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, de Vallière S, Kuhn A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, Alaimo C, Harbarth S, Poolman J, Fonck VG.

Lancet Infect Dis. 2017 May;17(5):528-537. doi: 10.1016/S1473-3099(17)30108-1. Epub 2017 Feb 24.

PMID:
28238601
7.

A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation from Immunogenicity.

Dowling DJ, Sanders H, Cheng WK, Joshi S, Brightman S, Bergelson I, Pietrasanta C, van Haren SD, van Amsterdam S, Fernandez J, van den Dobbelsteen GP, Levy O.

Front Immunol. 2016 Dec 8;7:562. doi: 10.3389/fimmu.2016.00562. eCollection 2016.

8.

Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models.

van den Dobbelsteen GPJM, Faé KC, Serroyen J, van den Nieuwenhof IM, Braun M, Haeuptle MA, Sirena D, Schneider J, Alaimo C, Lipowsky G, Gambillara-Fonck V, Wacker M, Poolman JT.

Vaccine. 2016 Jul 29;34(35):4152-4160. doi: 10.1016/j.vaccine.2016.06.067. Epub 2016 Jul 6.

PMID:
27395567
9.

Importance of (antibody-dependent) complement-mediated serum killing in protection against Bordetella pertussis.

Geurtsen J, Fae KC, van den Dobbelsteen GP.

Expert Rev Vaccines. 2014 Oct;13(10):1229-40. doi: 10.1586/14760584.2014.944901. Epub 2014 Aug 1. Review.

PMID:
25081731
10.

The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines.

Queenan AM, Fernandez J, Shang W, Wiertsema S, van den Dobbelsteen GP, Poolman J.

Expert Rev Vaccines. 2014 Oct;13(10):1265-70. doi: 10.1586/14760584.2014.938642. Epub 2014 Jul 17.

PMID:
25029905
11.

The history of pneumococcal conjugate vaccine development: dose selection.

Poolman JT, Peeters CC, van den Dobbelsteen GP.

Expert Rev Vaccines. 2013 Dec;12(12):1379-94. doi: 10.1586/14760584.2013.852475. Review.

PMID:
24195479
12.

Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose.

van Westen E, Rodenburg GD, van Gils EJ, Tcherniaeva I, Berbers GA, Cowell L, Goldblatt D, Rots NY, van den Dobbelsteen GP, Sanders EA.

Vaccine. 2013 Dec 2;31(49):5834-42. doi: 10.1016/j.vaccine.2013.09.073. Epub 2013 Oct 10.

13.

Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles.

Zariri A, van Dijken H, Hamstra HJ, van der Flier M, Vidarsson G, van Putten JP, Boog CJ, van den Dobbelsteen G, van der Ley P.

Vaccine. 2013 Nov 12;31(47):5585-93. doi: 10.1016/j.vaccine.2013.07.069. Epub 2013 Aug 6.

PMID:
23933369
14.

Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.

van de Waterbeemd B, Zomer G, Kaaijk P, Ruiterkamp N, Wijffels RH, van den Dobbelsteen GP, van der Pol LA.

PLoS One. 2013 May 31;8(5):e65157. doi: 10.1371/journal.pone.0065157. Print 2013.

15.

Superiority of trans-oral over trans-nasal sampling in detecting Streptococcus pneumoniae colonization in adults.

Trzciński K, Bogaert D, Wyllie A, Chu ML, van der Ende A, Bruin JP, van den Dobbelsteen G, Veenhoven RH, Sanders EA.

PLoS One. 2013;8(3):e60520. doi: 10.1371/journal.pone.0060520. Epub 2013 Mar 28.

16.

Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.

Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GP, Postma MJ.

Hum Vaccin Immunother. 2013 May;9(5):1129-38. doi: 10.4161/hv.23888. Epub 2013 Feb 13.

17.

Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease.

Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, van Dijken HH, van den Dobbelsteen GP.

Vaccine. 2013 Feb 4;31(7):1065-71. doi: 10.1016/j.vaccine.2012.12.031. Epub 2012 Dec 27.

PMID:
23273968
18.

Preclinical evaluation of MenB vaccines: prerequisites for clinical development.

Sanders H, Kaaijk P, van den Dobbelsteen GP.

Expert Rev Vaccines. 2013 Jan;12(1):31-42. doi: 10.1586/erv.12.137. Review.

PMID:
23256737
19.

Resurgence of pertussis calls for re-evaluation of pertussis animal models.

van der Ark AA, Hozbor DF, Boog CJ, Metz B, van den Dobbelsteen GP, van Els CA.

Expert Rev Vaccines. 2012 Sep;11(9):1121-37. doi: 10.1586/erv.12.83. Review.

PMID:
23151168
20.

Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

Rodenburg GD, Sanders EA, van Gils EJ, Veenhoven RH, Zborowski T, van den Dobbelsteen GP, Bloem AC, Berbers GA, Bogaert D.

PLoS One. 2012;7(10):e46916. doi: 10.1371/journal.pone.0046916. Epub 2012 Oct 16.

21.

Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis.

Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, Bogaert D, Wijmenga-Monsuur AJ, van den Dobbelsteen GP, Sanders EA.

PLoS One. 2012;7(6):e39730. doi: 10.1371/journal.pone.0039730. Epub 2012 Jun 25. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/2b5d32c3-808f-4759-8207-0a953e4ad01d.

22.

Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury.

Salha D, Szeto J, Myers L, Claus C, Sheung A, Tang M, Ljutic B, Hanwell D, Ogilvie K, Ming M, Messham B, van den Dobbelsteen G, Hopfer R, Ochs MM, Gallichan S.

Infect Immun. 2012 Jun;80(6):2212-20. doi: 10.1128/IAI.06348-11. Epub 2012 Apr 2.

23.

Nonclinical vaccine safety evaluation: advantages of continuous temperature monitoring using abdominally implanted data loggers.

Kaaijk P, van der Ark AA, van Amerongen G, van den Dobbelsteen GP.

J Appl Toxicol. 2013 Jun;33(6):521-6. doi: 10.1002/jat.2720. Epub 2012 Mar 8.

PMID:
22407801
24.

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.

Kaaijk P, van der Ende A, Berbers G, van den Dobbelsteen GP, Rots NY.

BMC Infect Dis. 2012 Feb 8;12:35. doi: 10.1186/1471-2334-12-35.

25.

Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae.

Rodenburg GD, van Gils EJ, Veenhoven RH, Bogaert D, van den Dobbelsteen GP, Berbers GA, Sanders EA.

J Pediatr. 2011 Dec;159(6):965-70.e1. doi: 10.1016/j.jpeds.2011.06.011. Epub 2011 Aug 2.

PMID:
21813135
26.

Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.

van der Ley P, van den Dobbelsteen G.

Hum Vaccin. 2011 Aug;7(8):886-90. doi: 10.4161/hv.7.8.16086. Epub 2011 Aug 1.

PMID:
21785281
27.

A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques.

Hoogerhout P, Kamphuis W, Brugghe HF, Sluijs JA, Timmermans HA, Westdijk J, Zomer G, Boog CJ, Hol EM, van den Dobbelsteen GP.

PLoS One. 2011 Apr 19;6(4):e19110. doi: 10.1371/journal.pone.0019110.

28.

Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands.

Spijkerman J, van Gils EJ, Veenhoven RH, Hak E, Yzerman EP, van der Ende A, Wijmenga-Monsuur AJ, van den Dobbelsteen GP, Sanders EA.

Emerg Infect Dis. 2011 Apr;17(4):584-91. doi: 10.3201/eid1704.101115.

29.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

PMID:
20519267
30.

The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease.

Fransen F, Hamstra HJ, Boog CJ, van Putten JP, van den Dobbelsteen GP, van der Ley P.

Infect Immun. 2010 Jul;78(7):3177-86. doi: 10.1128/IAI.01311-09. Epub 2010 May 3.

31.

Quality-control issues and approaches in vaccine development.

Metz B, van den Dobbelsteen G, van Els C, van der Gun J, Levels L, van der Pol L, Rots N, Kersten G.

Expert Rev Vaccines. 2009 Feb;8(2):227-38. doi: 10.1586/14760584.8.2.227. Review.

PMID:
19196202
32.

Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model.

Luijkx TA, van Gaans-van den Brink JA, van Dijken HH, van den Dobbelsteen GP, van Els CA.

Clin Vaccine Immunol. 2008 Oct;15(10):1598-605. doi: 10.1128/CVI.00192-08. Epub 2008 Sep 3.

33.

Bioneedles as vaccine carriers.

Hirschberg HJ, van de Wijdeven GG, Kelder AB, van den Dobbelsteen GP, Kersten GF.

Vaccine. 2008 May 2;26(19):2389-97. doi: 10.1016/j.vaccine.2008.02.067. Epub 2008 Mar 25.

PMID:
18406021
34.

Meningococcal B vaccine development and evaluation of efficacy.

van Alphen L, van den Dobbelsteen G.

Hum Vaccin. 2008 Mar-Apr;4(2):158-61. Epub 2007 Aug 14.

PMID:
18388494
35.

On the design of national vaccination programmes.

van der Zeijst BA, Dijkman MI, Luytjes W, van Alphen AJ, van den Dobbelsteen GP.

Vaccine. 2007 Apr 20;25(16):3143-5. Epub 2007 Jan 29. Review.

PMID:
17293011
36.

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs.

van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L.

Vaccine. 2007 Mar 22;25(13):2491-6. Epub 2006 Sep 20.

PMID:
17023098
37.

CC and CXC chemokine levels in children with meningococcal sepsis accurately predict mortality and disease severity.

Vermont CL, Hazelzet JA, de Kleijn ED, van den Dobbelsteen GP, de Groot R.

Crit Care. 2006 Feb;10(1):R33.

38.

Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine.

Luijkx T, van Dijken H, van Els C, van den Dobbelsteen G.

Vaccine. 2006 Mar 6;24(10):1569-77. Epub 2005 Oct 24.

PMID:
16298029
39.

Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease.

Vidarsson G, Overbeeke N, Stemerding AM, van den Dobbelsteen G, van Ulsen P, van der Ley P, Kilian M, van de Winkel JG.

Infect Immun. 2005 Oct;73(10):6721-6.

40.

Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children.

Findlow J, Lowe A, Deane S, Balmer P, van den Dobbelsteen G, Dawson M, Andrews N, Borrow R.

Vaccine. 2005 Apr 8;23(20):2623-7.

PMID:
15780445
41.

Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease.

Vermont CL, van Dijken HH, de Groot R, van den Dobbelsteen GP.

Pediatr Res. 2005 Jul;58(1):149-52. Epub 2005 Mar 17.

PMID:
15774845
42.

Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.

Welte R, van den Dobbelsteen G, Bos JM, de Melker H, van Alphen L, Spanjaard L, Rümke HC, Postma MJ.

Vaccine. 2004 Dec 9;23(4):470-9.

PMID:
15530695
43.

PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.

Vermont CL, Van Dijken HH, De Groot R, Van Alphen L, Van Den Dobbelsteen GP.

Vaccine. 2004 Aug 13;22(23-24):3008-13.

PMID:
15297049
44.

Meningococcal serogroup B infections: a search for a broadly protective vaccine.

Vermont CL, van den Dobbelsteen GP.

Expert Rev Vaccines. 2003 Oct;2(5):673-81. Review.

PMID:
14711328
45.

Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.

Luijkx TA, van Dijken H, Hamstra HJ, Kuipers B, van der Ley P, van Alphen L, van den Dobbelsteen G.

Infect Immun. 2003 Nov;71(11):6367-71.

46.

Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Wedege E, Kuipers B, Bolstad K, van Dijken H, Frøholm LO, Vermont C, Caugant DA, van den Dobbelsteen G.

Infect Immun. 2003 Jul;71(7):3775-81.

47.

Recent developments in vaccines to prevent meningococcal serogroup B infections.

Vermont CL, van den Dobbelsteen GP, de Groot R.

Curr Opin Mol Ther. 2003 Feb;5(1):33-8. Review.

PMID:
12669468
48.

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP.

Infect Immun. 2003 Apr;71(4):1650-5.

49.

Neisseria meningitidis serogroup B: laboratory correlates of protection.

Vermont C, van den Dobbelsteen G.

FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):89-96. Review.

50.

Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP.

Infect Immun. 2002 Feb;70(2):584-90.

Supplemental Content

Loading ...
Support Center